Employee v Zogenix (AUTH/3567/10/21): Advisory board concerns in Eastern Europe – no breach

📅 2021 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3567/10/21
PartiesEmployee v Zogenix
IssueConcerns about arrangements for advisory boards (Croatia, Poland, Hungary), certification, third-party use, and alleged conflicts of interest
Complaint received4 October 2021
Case completed11 August 2022
Applicable Code year2021
Panel decisionNo breach of the Code
Clauses considered2; 5.1; 8.1; 8.2; 19.1; 24.2
Advisory boards took place?No (none had taken place at time of complaint)
Payments made?No
AppealNo appeal

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous, non-contactable employee alleged a senior medical employee planned advisory boards in Croatia, Poland and Hungary despite Zogenix having no presence there, creating inappropriate expectations among HCPs.
  • Allegations included use of consultants/contractors without sufficient local compliance knowledge, inappropriate certification in Veeva, and signatories not involved in the work.
  • Further allegations included attempts to influence hourly rates and a conflict of interest via the employee’s partner participating in paid activities.
  • Additional concerns were raised about a consultant lacking a contract for medical activities and advising non-compliant sponsorship/payments.
  • Zogenix postponed the Croatia advisory board (scheduled 8 Oct 2021) to conduct an internal investigation; Poland and Hungary were only in early planning and not finalised.
  • Zogenix provided documentation for the Croatia advisory board (invitation, agenda, advisor selection/honorarium, arrangements) with certification by a final medical signatory; other materials were still in development.
  • At the time of the complaint, none of the advisory boards had taken place and no payments had been made.
⚖️

Outcome

  • No breach of the ABPI Code (2021).
  • The Panel found the complainant did not prove, on the balance of probabilities, that the planned advisory boards would fail Code requirements or that proposed payments would be inappropriate.
  • The Panel found no evidence that certification was done by the person who developed/drew up the materials (as alleged).
  • The Panel found the complainant did not establish failures to maintain high standards regarding alleged conflicts of interest, sponsorship/payment issues, or alleged retaliation against consultants.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training